Hank was designed to help rehabilitate adults who have suffered a neurological injury. The system can also be used for gait compensation in patients who have paralysis of the lower limbs after a spinal cord injury.
The company suggests that the exoskeleton system is the first exoskeleton to receive CE Mark approval for clinical use. It is also one of the first exoskeletons to have motorized ankles that allow for more natural range of motion.
“CE Mark approval is a significant accomplishment for us, the exoskeleton required rigorous regulatory review against high-clinical and safety standards,” said Carlos Fernandez, CEO of Gogoa Mobility Robots. “Europe is the new hotbed for start-ups in the robotic rehabilitation field and we are proud to be the first EU company to get the certification. It represents the validation of our strategic road map, product development and the quality our system. We look forward to introducing Hank in different countries in partnership with distributors to help more people improve their quality of life.”
Gogoa Mobility Robots is now able to market and sell Hank in EU market countries while developing effective robotic rehabilitation. The Hank system meets Medical Device Directive requirements as well.